Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,401
archived clinical trials in
Alzheimer Disease

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
A Randomized, Multicenter, Multicountry Study to Evaluate the Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and to Evaluate the Relationship Between Florbetapir (18F) PET Scan Status and Cognitive Decline
Status: Enrolling
Updated:  8/2/2013
Clinical Research Facility
mi
from
Greensboro, NC
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
A Randomized, Multicenter, Multicountry Study to Evaluate the Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and to Evaluate the Relationship Between Florbetapir (18F) PET Scan Status and Cognitive Decline
Status: Enrolling
Updated: 8/2/2013
Clinical Research Facility
mi
from
Greensboro, NC
Click here to add this to my saved trials
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
A Randomized, Multicenter, Multicountry Study to Evaluate the Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and to Evaluate the Relationship Between Florbetapir (18F) PET Scan Status and Cognitive Decline
Status: Enrolling
Updated:  8/2/2013
Clinical Research Facility
mi
from
Providence, RI
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
A Randomized, Multicenter, Multicountry Study to Evaluate the Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and to Evaluate the Relationship Between Florbetapir (18F) PET Scan Status and Cognitive Decline
Status: Enrolling
Updated: 8/2/2013
Clinical Research Facility
mi
from
Providence, RI
Click here to add this to my saved trials
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
A Randomized, Multicenter, Multicountry Study to Evaluate the Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and to Evaluate the Relationship Between Florbetapir (18F) PET Scan Status and Cognitive Decline
Status: Enrolling
Updated:  8/2/2013
Clinical Research Facility
mi
from
Providence, RI
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
A Randomized, Multicenter, Multicountry Study to Evaluate the Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and to Evaluate the Relationship Between Florbetapir (18F) PET Scan Status and Cognitive Decline
Status: Enrolling
Updated: 8/2/2013
Clinical Research Facility
mi
from
Providence, RI
Click here to add this to my saved trials
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
A Randomized, Multicenter, Multicountry Study to Evaluate the Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and to Evaluate the Relationship Between Florbetapir (18F) PET Scan Status and Cognitive Decline
Status: Enrolling
Updated:  8/2/2013
Clinical Research Facility
mi
from
Salt Lake City, UT
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
A Randomized, Multicenter, Multicountry Study to Evaluate the Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and to Evaluate the Relationship Between Florbetapir (18F) PET Scan Status and Cognitive Decline
Status: Enrolling
Updated: 8/2/2013
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
A Randomized, Multicenter, Multicountry Study to Evaluate the Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and to Evaluate the Relationship Between Florbetapir (18F) PET Scan Status and Cognitive Decline
Status: Enrolling
Updated:  8/2/2013
Clinical Research Facility
mi
from
Bennington, VT
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
A Randomized, Multicenter, Multicountry Study to Evaluate the Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and to Evaluate the Relationship Between Florbetapir (18F) PET Scan Status and Cognitive Decline
Status: Enrolling
Updated: 8/2/2013
Clinical Research Facility
mi
from
Bennington, VT
Click here to add this to my saved trials
A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease
A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  8/20/2013
James J. Peters Veterans Affairs Medical Center
mi
from
Bronx, NY
A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease
A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 8/20/2013
James J. Peters Veterans Affairs Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Effects of a Combined Transcranial Magnetic Stimulation (TMS) and Cognitive Training in Alzheimer Patients
Effects of a Combined TMS and Cognitive Training in Alzheimer Patients: A Single-Center, Randomized, Double-Blind, Placebo-Controlled Study
Status: Enrolling
Updated:  9/9/2013
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Effects of a Combined Transcranial Magnetic Stimulation (TMS) and Cognitive Training in Alzheimer Patients
Effects of a Combined TMS and Cognitive Training in Alzheimer Patients: A Single-Center, Randomized, Double-Blind, Placebo-Controlled Study
Status: Enrolling
Updated: 9/9/2013
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  10/1/2013
Local Institution
mi
from
Tucson, AZ
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 10/1/2013
Local Institution
mi
from
Tucson, AZ
Click here to add this to my saved trials
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  10/1/2013
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 10/1/2013
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
Click here to add this to my saved trials
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  10/1/2013
Collaborative Neuroscience Network
mi
from
Garden Grove, CA
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 10/1/2013
Collaborative Neuroscience Network
mi
from
Garden Grove, CA
Click here to add this to my saved trials
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  10/1/2013
UCSF Memory and Aging Center
mi
from
San Francisco, CA
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 10/1/2013
UCSF Memory and Aging Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  10/1/2013
Alpine Clinical Research Center
mi
from
Boulder, CO
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 10/1/2013
Alpine Clinical Research Center
mi
from
Boulder, CO
Click here to add this to my saved trials
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  10/1/2013
Associated Neurologists of Southern Connecticut, PC
mi
from
Fairfield, CT
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 10/1/2013
Associated Neurologists of Southern Connecticut, PC
mi
from
Fairfield, CT
Click here to add this to my saved trials
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  10/1/2013
Compass Research LLC
mi
from
Orlando, FL
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 10/1/2013
Compass Research LLC
mi
from
Orlando, FL
Click here to add this to my saved trials
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  10/1/2013
Palm Beach Neurological Center Advanced Research Consultants
mi
from
Palm Beach Gardens, FL
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 10/1/2013
Palm Beach Neurological Center Advanced Research Consultants
mi
from
Palm Beach Gardens, FL
Click here to add this to my saved trials
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  10/1/2013
Local Institution
mi
from
Atlanta, GA
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 10/1/2013
Local Institution
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  10/1/2013
Alexian Brothers Neurosciences Institute Clinical Research
mi
from
Elk Grove Village, IL
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 10/1/2013
Alexian Brothers Neurosciences Institute Clinical Research
mi
from
Elk Grove Village, IL
Click here to add this to my saved trials
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  10/1/2013
Brigham and Women's Hosp
mi
from
Boston, MA
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 10/1/2013
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  10/1/2013
Michigan State University
mi
from
Lansing, MI
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 10/1/2013
Michigan State University
mi
from
Lansing, MI
Click here to add this to my saved trials
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  10/1/2013
Ohio State University
mi
from
Columbus, OH
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 10/1/2013
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  10/1/2013
The Clinical Trial Center, LLC
mi
from
Jenkintown, PA
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 10/1/2013
The Clinical Trial Center, LLC
mi
from
Jenkintown, PA
Click here to add this to my saved trials
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  10/1/2013
Penn Memory Center
mi
from
Philadelphia, PA
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 10/1/2013
Penn Memory Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  10/1/2013
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 10/1/2013
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  10/1/2013
Lifetree Clinical Research
mi
from
Salt Lake City, UT
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 10/1/2013
Lifetree Clinical Research
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
A Multicenter, Open-label Extension, Multiple-dose, Parallel Group Study to Investigate the Long-term Safety and Tolerability of AAB-003 (PF-05236812) Administered Intravenously in Subjects With Mild to Moderate Alzheimer's Disease Previously Treated With AAB-003 or Placebo in Protocol B2601001
Status: Enrolling
Updated:  10/11/2013
Pfizer Investigational Site
mi
from
Atlantis, FL
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
A Multicenter, Open-label Extension, Multiple-dose, Parallel Group Study to Investigate the Long-term Safety and Tolerability of AAB-003 (PF-05236812) Administered Intravenously in Subjects With Mild to Moderate Alzheimer's Disease Previously Treated With AAB-003 or Placebo in Protocol B2601001
Status: Enrolling
Updated: 10/11/2013
Pfizer Investigational Site
mi
from
Atlantis, FL
Click here to add this to my saved trials
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
A Multicenter, Open-label Extension, Multiple-dose, Parallel Group Study to Investigate the Long-term Safety and Tolerability of AAB-003 (PF-05236812) Administered Intravenously in Subjects With Mild to Moderate Alzheimer's Disease Previously Treated With AAB-003 or Placebo in Protocol B2601001
Status: Enrolling
Updated:  10/11/2013
Pfizer Investigational Site
mi
from
Atlanta, GA
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
A Multicenter, Open-label Extension, Multiple-dose, Parallel Group Study to Investigate the Long-term Safety and Tolerability of AAB-003 (PF-05236812) Administered Intravenously in Subjects With Mild to Moderate Alzheimer's Disease Previously Treated With AAB-003 or Placebo in Protocol B2601001
Status: Enrolling
Updated: 10/11/2013
Pfizer Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
A Multicenter, Open-label Extension, Multiple-dose, Parallel Group Study to Investigate the Long-term Safety and Tolerability of AAB-003 (PF-05236812) Administered Intravenously in Subjects With Mild to Moderate Alzheimer's Disease Previously Treated With AAB-003 or Placebo in Protocol B2601001
Status: Enrolling
Updated:  10/11/2013
Pfizer Investigational Site
mi
from
Baltimore, MD
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
A Multicenter, Open-label Extension, Multiple-dose, Parallel Group Study to Investigate the Long-term Safety and Tolerability of AAB-003 (PF-05236812) Administered Intravenously in Subjects With Mild to Moderate Alzheimer's Disease Previously Treated With AAB-003 or Placebo in Protocol B2601001
Status: Enrolling
Updated: 10/11/2013
Pfizer Investigational Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
A Multicenter, Open-label Extension, Multiple-dose, Parallel Group Study to Investigate the Long-term Safety and Tolerability of AAB-003 (PF-05236812) Administered Intravenously in Subjects With Mild to Moderate Alzheimer's Disease Previously Treated With AAB-003 or Placebo in Protocol B2601001
Status: Enrolling
Updated:  10/11/2013
Pfizer Investigational Site
mi
from
Detroit, MI
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
A Multicenter, Open-label Extension, Multiple-dose, Parallel Group Study to Investigate the Long-term Safety and Tolerability of AAB-003 (PF-05236812) Administered Intravenously in Subjects With Mild to Moderate Alzheimer's Disease Previously Treated With AAB-003 or Placebo in Protocol B2601001
Status: Enrolling
Updated: 10/11/2013
Pfizer Investigational Site
mi
from
Detroit, MI
Click here to add this to my saved trials
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
A Multicenter, Open-label Extension, Multiple-dose, Parallel Group Study to Investigate the Long-term Safety and Tolerability of AAB-003 (PF-05236812) Administered Intravenously in Subjects With Mild to Moderate Alzheimer's Disease Previously Treated With AAB-003 or Placebo in Protocol B2601001
Status: Enrolling
Updated:  10/11/2013
Pfizer Investigational Site
mi
from
Biloxi, MS
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
A Multicenter, Open-label Extension, Multiple-dose, Parallel Group Study to Investigate the Long-term Safety and Tolerability of AAB-003 (PF-05236812) Administered Intravenously in Subjects With Mild to Moderate Alzheimer's Disease Previously Treated With AAB-003 or Placebo in Protocol B2601001
Status: Enrolling
Updated: 10/11/2013
Pfizer Investigational Site
mi
from
Biloxi, MS
Click here to add this to my saved trials
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
A Multicenter, Open-label Extension, Multiple-dose, Parallel Group Study to Investigate the Long-term Safety and Tolerability of AAB-003 (PF-05236812) Administered Intravenously in Subjects With Mild to Moderate Alzheimer's Disease Previously Treated With AAB-003 or Placebo in Protocol B2601001
Status: Enrolling
Updated:  10/11/2013
Pfizer Investigational Site
mi
from
Cape Girardeau, MO
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
A Multicenter, Open-label Extension, Multiple-dose, Parallel Group Study to Investigate the Long-term Safety and Tolerability of AAB-003 (PF-05236812) Administered Intravenously in Subjects With Mild to Moderate Alzheimer's Disease Previously Treated With AAB-003 or Placebo in Protocol B2601001
Status: Enrolling
Updated: 10/11/2013
Pfizer Investigational Site
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
A Multicenter, Open-label Extension, Multiple-dose, Parallel Group Study to Investigate the Long-term Safety and Tolerability of AAB-003 (PF-05236812) Administered Intravenously in Subjects With Mild to Moderate Alzheimer's Disease Previously Treated With AAB-003 or Placebo in Protocol B2601001
Status: Enrolling
Updated:  10/11/2013
Pfizer Investigational Site
mi
from
Clifton, NJ
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
A Multicenter, Open-label Extension, Multiple-dose, Parallel Group Study to Investigate the Long-term Safety and Tolerability of AAB-003 (PF-05236812) Administered Intravenously in Subjects With Mild to Moderate Alzheimer's Disease Previously Treated With AAB-003 or Placebo in Protocol B2601001
Status: Enrolling
Updated: 10/11/2013
Pfizer Investigational Site
mi
from
Clifton, NJ
Click here to add this to my saved trials
Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease
Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease
Status: Enrolling
Updated:  11/8/2013
Veterans Affairs Puget Sound Health Care System
mi
from
Seattle, WA
Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease
Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease
Status: Enrolling
Updated: 11/8/2013
Veterans Affairs Puget Sound Health Care System
mi
from
Seattle, WA
Click here to add this to my saved trials
Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls
Evaluation of [18F] CFPyPB PET as a Marker of Glycine Transporter-1 (GlyT1) Receptor in Subjects With Parkinson Disease, Alzheimer Disease and Healthy Subjects
Status: Enrolling
Updated:  11/8/2013
Molecular Neuroimaging, LLC
mi
from
New Haven, CT
Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls
Evaluation of [18F] CFPyPB PET as a Marker of Glycine Transporter-1 (GlyT1) Receptor in Subjects With Parkinson Disease, Alzheimer Disease and Healthy Subjects
Status: Enrolling
Updated: 11/8/2013
Molecular Neuroimaging, LLC
mi
from
New Haven, CT
Click here to add this to my saved trials
The Feasibility of Florbetapir Quantitation
Status: Enrolling
Updated:  11/21/2013
Clinical Research Facility
mi
from
Philadelphia, PA
The Feasibility of Florbetapir Quantitation
Status: Enrolling
Updated: 11/21/2013
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Positron Emission Tomography (PET) Study Evaluating Brain Metabolism of a Medical Food in Alzheimer's Disease
A Single-site Positron Emission Tomography (PET) Study of the Cerebral Metabolic Effects of AC-1202 (Axona®) Treatment in Mild-to-Moderate Alzheimer's Disease (AD)
Status: Enrolling
Updated:  11/23/2013
200 Medical Plaza, UCLA Medical Center
mi
from
Los Angeles, CA
A Positron Emission Tomography (PET) Study Evaluating Brain Metabolism of a Medical Food in Alzheimer's Disease
A Single-site Positron Emission Tomography (PET) Study of the Cerebral Metabolic Effects of AC-1202 (Axona®) Treatment in Mild-to-Moderate Alzheimer's Disease (AD)
Status: Enrolling
Updated: 11/23/2013
200 Medical Plaza, UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Positron Emission Tomography (PET) Study Evaluating Brain Metabolism of a Medical Food in Alzheimer's Disease
A Single-site Positron Emission Tomography (PET) Study of the Cerebral Metabolic Effects of AC-1202 (Axona®) Treatment in Mild-to-Moderate Alzheimer's Disease (AD)
Status: Enrolling
Updated:  11/23/2013
Center for Neurotherapeutics at UCLA
mi
from
Los Angeles, CA
A Positron Emission Tomography (PET) Study Evaluating Brain Metabolism of a Medical Food in Alzheimer's Disease
A Single-site Positron Emission Tomography (PET) Study of the Cerebral Metabolic Effects of AC-1202 (Axona®) Treatment in Mild-to-Moderate Alzheimer's Disease (AD)
Status: Enrolling
Updated: 11/23/2013
Center for Neurotherapeutics at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Two-Part, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Effect on Biomarkers of AZD3293 in Plasma and Cerebrospinal Fluid in Healthy Male and Non-Fertile Female Elderly Volunteers and in Mild-to-Moderate Alzheimer Disease Patients
Status: Enrolling
Updated:  12/4/2013
Clinical Research Facility
mi
from
Glendale, CA
A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Two-Part, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Effect on Biomarkers of AZD3293 in Plasma and Cerebrospinal Fluid in Healthy Male and Non-Fertile Female Elderly Volunteers and in Mild-to-Moderate Alzheimer Disease Patients
Status: Enrolling
Updated: 12/4/2013
Clinical Research Facility
mi
from
Glendale, CA
Click here to add this to my saved trials
A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Two-Part, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Effect on Biomarkers of AZD3293 in Plasma and Cerebrospinal Fluid in Healthy Male and Non-Fertile Female Elderly Volunteers and in Mild-to-Moderate Alzheimer Disease Patients
Status: Enrolling
Updated:  12/4/2013
Clinical Research Facility
mi
from
Glendale, CA
A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Two-Part, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Effect on Biomarkers of AZD3293 in Plasma and Cerebrospinal Fluid in Healthy Male and Non-Fertile Female Elderly Volunteers and in Mild-to-Moderate Alzheimer Disease Patients
Status: Enrolling
Updated: 12/4/2013
Clinical Research Facility
mi
from
Glendale, CA
Click here to add this to my saved trials
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment
Status: Enrolling
Updated:  1/7/2014
Memory Enhancement Center of America, Inc.
mi
from
Eatontown, NJ
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment
Status: Enrolling
Updated: 1/7/2014
Memory Enhancement Center of America, Inc.
mi
from
Eatontown, NJ
Click here to add this to my saved trials
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment
Status: Enrolling
Updated:  1/7/2014
Memory Center of New Jersey, Inc.
mi
from
Monroe Twp, NJ
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment
Status: Enrolling
Updated: 1/7/2014
Memory Center of New Jersey, Inc.
mi
from
Monroe Twp, NJ
Click here to add this to my saved trials
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment
Status: Enrolling
Updated:  1/7/2014
Memory Enhancement Center Of Nj, Inc.
mi
from
Toms River, NJ
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment
Status: Enrolling
Updated: 1/7/2014
Memory Enhancement Center Of Nj, Inc.
mi
from
Toms River, NJ
Click here to add this to my saved trials
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment
Status: Enrolling
Updated:  1/7/2014
Senior Adults Specialty Research
mi
from
Austin, TX
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment
Status: Enrolling
Updated: 1/7/2014
Senior Adults Specialty Research
mi
from
Austin, TX
Click here to add this to my saved trials
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment
Status: Enrolling
Updated:  1/7/2014
Clinica Santa Maria, Div Neurologia
mi
from
Castellanza,
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment
Status: Enrolling
Updated: 1/7/2014
Clinica Santa Maria, Div Neurologia
mi
from
Castellanza,
Click here to add this to my saved trials
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patient With Mild Cognitive Impairment
Status: Enrolling
Updated:  1/7/2014
Memory Enhancement Center of America, Inc.
mi
from
Eatontown, NJ
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patient With Mild Cognitive Impairment
Status: Enrolling
Updated: 1/7/2014
Memory Enhancement Center of America, Inc.
mi
from
Eatontown, NJ
Click here to add this to my saved trials
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patient With Mild Cognitive Impairment
Status: Enrolling
Updated:  1/7/2014
Memory Center of New Jersey, Inc.
mi
from
Monroe Twp, NJ
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patient With Mild Cognitive Impairment
Status: Enrolling
Updated: 1/7/2014
Memory Center of New Jersey, Inc.
mi
from
Monroe Twp, NJ
Click here to add this to my saved trials
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patient With Mild Cognitive Impairment
Status: Enrolling
Updated:  1/7/2014
Memory Enhancement Center Of Nj, Inc.
mi
from
Toms River, NJ
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patient With Mild Cognitive Impairment
Status: Enrolling
Updated: 1/7/2014
Memory Enhancement Center Of Nj, Inc.
mi
from
Toms River, NJ
Click here to add this to my saved trials
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patient With Mild Cognitive Impairment
Status: Enrolling
Updated:  1/7/2014
Senior Adults Specialty Research
mi
from
Austin, TX
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patient With Mild Cognitive Impairment
Status: Enrolling
Updated: 1/7/2014
Senior Adults Specialty Research
mi
from
Austin, TX
Click here to add this to my saved trials
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patient With Mild Cognitive Impairment
Status: Enrolling
Updated:  1/7/2014
Osp. Niguarda Ca'Granda, Dip. Di Neuroscienze
mi
from
Milano,
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patient With Mild Cognitive Impairment
Status: Enrolling
Updated: 1/7/2014
Osp. Niguarda Ca'Granda, Dip. Di Neuroscienze
mi
from
Milano,
Click here to add this to my saved trials
Study to Evaluate Dietary Supplementation With a Version of Anatabloc(R) in Subjects With Alzheimer's Disease
3-Month, Single Site or Multi-Site, Double Blind, Randomized, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety Tolerability and Potential Effects of the Dietary Supplement Anatabloc(R) in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  1/15/2014
Roskamp Institute
mi
from
Sarasota, FL
Study to Evaluate Dietary Supplementation With a Version of Anatabloc(R) in Subjects With Alzheimer's Disease
3-Month, Single Site or Multi-Site, Double Blind, Randomized, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety Tolerability and Potential Effects of the Dietary Supplement Anatabloc(R) in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 1/15/2014
Roskamp Institute
mi
from
Sarasota, FL
Click here to add this to my saved trials
A Study of 18F-AV-1451 in Healthy Volunteers and Cognitively Impaired Subjects
Test-Retest Reproducibility of 18F-AV-1451 Injection for Brain Imaging of Tau in Healthy Volunteers and Cognitively Impaired Subjects.
Status: Enrolling
Updated:  2/7/2014
Clinical Research Facility
mi
from
Newport Beach, CA
A Study of 18F-AV-1451 in Healthy Volunteers and Cognitively Impaired Subjects
Test-Retest Reproducibility of 18F-AV-1451 Injection for Brain Imaging of Tau in Healthy Volunteers and Cognitively Impaired Subjects.
Status: Enrolling
Updated: 2/7/2014
Clinical Research Facility
mi
from
Newport Beach, CA
Click here to add this to my saved trials